Abstract:OBJECTIVE:To explore the effects of cannabinoid 2 receptor (CB2) in the development of bone cancer pain in mice.METHODS:A total of 84 mice (C3H/HeJ) were randomly divided into 4 groups:tumor group (Group T, n = 30), medication administration group (Group J, n = 12), vehicle group (Group D, n = 12) and sham group (Group S, n = 30). And 2 × 10(5) osteolytic NCTC2472 cells in α-MEM were injected into medullary cavity of right distal femur to induce bone cancer pain in a murine model while sham mice received an injection of only α-MEM. All mice were tested for pain-related behaviors at pre-inoculation and at Days 5, 7, 10 and 14 post-inoculation. The tests included paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL). Group J and Group D were injected intrathecally with 2 µg JWH015 dissolved in 4% DMSO and only 4% DMSO respectively in a 5 µl. volume. Pain behavior tests were performed before and at 1, 6, 24, 48 and 72 h after an intrathecal injection. Lumbar intumescentia of mice in each group were harvested to examine the expression level of CB2 by Western blot after pain behavior tests at Days 5, 7, 10 and 14 post-inoculation and 12 h after an intrathecal injection.RESULTS:(1) Pain behavior tests:Mechanical allodynia appeared at Day 7 post-inoculation. The value of PWMT was (1.27 ± 0.28) g (P < 0.05) and it declined gradually to (0.53 ± 0.20) g at Day 14. The threshold of mechanical hyperalgesia increased to (1.00 ± 0.20) g at 6 h after an intrathecal injection of JWH015, peaked at (1.40 ± 0.39) g at 12 h, became alleviated after 48 h and recovered to the pre-dosing levels at 72 h. Thermal hyperalgesia appeared at Day 10 post-inoculation. The value of PWTL was (16.9 ± 0.4) s (P < 0.05) at Day 10 and declined to (11.5 ± 0.7) s at Day 14 post-inoculation. The threshold of thermal hyperalgesia increased to (15.7 ± 1.9) g at 6 h after an intrathecal injection of JWH015, peaked at (18.6 ± 2.3) g at 12 h, became alleviated after 48 h and recovered to the pre-dosing levels at 72 h. (2) Western blot: From Day 5 post-inoculation, the ratio of CB2/β-actin increased gradually. Compared with the ratio of 0.190 ± 0.010 at Day 5 post-inoculation, the ratio of CB2/β-actin increased to 0.660 ± 0.010 at Day 14 post-inoculation (P < 0.05); compared with the ratio of 0.903 ± 0.006 in group D at 12 h after an intrathecal injection of JWH015, the ratio of CB2/β-actin 0.510 ± 0.010 significantly decreased (P < 0.05).CONCLUSION:The cannabinoid 2 receptor plays an important role in the formation of bone cancer pain.

Involvement of the Spinal NMDA Receptor/pkcγ Signaling Pathway in the Development of Bone Cancer Pain

The Role of N‐methyl‐d‐aspartate Receptor Subunit NR2B in Spinal Cord in Cancer Pain

Participation of spinal CaMKII-NR2B signal pathway in the development of bone cancer pain in mice

The Inhibitor of Calcium/calmodulin-Dependent Protein Kinase II KN93 Attenuates Bone Cancer Pain Via Inhibition of KIF17/NR2B Trafficking in Mice

Role of nitric oxide synthase in the development of bone cancer pain and effect of L‑NMMA.

Activation of the Camp-Pka Signaling Pathway in Rat Dorsal Root Ganglion and Spinal Cord Contributes Toward Induction and Maintenance of Bone Cancer Pain.

The role of neuronal nitric oxide synthase in the development of bone cancer pain

Activation of Spinal Mrgc-Gi-Nr2b-Nnos Signaling Pathway by Mas Oncogene-Related Gene C Receptor Agonist Bovine Adrenal Medulla 8-22 Attenuates Bone Cancer Pain in Mice

Role of spinal cord TNF-α in the development of bone cancer pain in mice

Extracellular Signal-Regulated Kinase Activation in Spinal Astrocytes and Microglia Contributes to Cancer-Induced Bone Pain in Rats

Pain Behavior and the Expression of Phosphorylated Camp Response Element Binding Protein and Brain-Derived Neurotrophic Factor in Dorsal Horn of Spinal Cord in a Mouse Model of Bone Cancer Pain

Intrathecal Injection of Metabotropic Glutamate Receptor Subtype 3 and 5 Agonist/Antagonist Attenuates Bone Cancer Pain by Inhibition of Spinal Astrocyte Activation in a Mouse Model

Dorsal root ganglia NR2B-mediated Epac1-Piezo2 signaling pathway contributes to mechanical allodynia of bone cancer pain

Endoplasmic Reticulum Stress Contributes to Nociception Via Neuroinflammation in a Murine Bone Cancer Pain Model.

Suppression of KCNQ/M (kv7) Potassium Channels in the Spinal Cord Contributes to the Sensitization of Dorsal Horn WDR Neurons and Pain Hypersensitivity in a Rat Model of Bone Cancer Pain.

Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord

Intrathecal Injection of the Peptide Myr-NR2B9c Attenuates Bone Cancer Pain Via Perturbing N-Methyl-D-Aspartate Receptor-PSD-95 Protein Interactions in Mice

Intrathecal Injection of Selected Peptide Myr-RC-13 Attenuates Bone Cancer Pain by Inhibiting KIF17 and NR2B Expression

Effect of Intrathecal Injection of Ifenprodil on the Expression of 2B Subunit Mrna of NMDA Receptor in Spinal Cord in a Mouse Model of Bone Cancer Pain

Role of Cannabinoid 2 Receptor in the Development of Bone Cancer Pain

Brain‐derived Neurotrophic Factor Modulates N‐methyl‐D‐aspartate Receptor Activation in a Rat Model of Cancer‐induced Bone Pain